Stocks · Healthcare · Biotechnology
Prelude Therapeutics Incorporated PRLD
$3.67 -3.17% Close, Oct 2, 2026 · NASDAQ · Market cap $208.9M
Strong growthHigh risk
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $22.4M, up 220.3% from a year earlier, accelerating from 138.9% a quarter earlier.
- Operating margin widened to -300.6% from -1928.7% a year earlier.
- The diluted share count rose 29.5% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 6%
- Revenue growth accelerationTop 4%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 30%
- Gross marginTop 8%
- Operating marginBottom 21%
- Accruals (lower is better)Top 23%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 31%
- Free-cash-flow yieldBottom 29%
- EBITDA / enterprise valueBottom 22%
- Sales / enterprise valueBottom 33%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 5%
- 6-month returnBottom 49%
- 1-year return vs S&P 500Top 8%
- Distance from 52-week highBottom 33%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 16%
- Consecutive EPS beatsTop 8%
- Share of analysts rating BuyBottom 28%
- Upside to consensus price targetTop 33%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 15%
- Maximum drawdown, 3 yearsBottom 15%
- Beta vs S&P 500 (lower is better)Bottom 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 138.9% | 220.3% | ↑ |
| Gross margin | 100.0% | 98.3% | ↓ |
| Operating margin | -1928.7% | -300.6% | ↑ |
| FCF margin | -1550.4% | -148.3% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 220.3% | 138.9% | ↑ | Top 6% |
| Gross margin | 98.3% | 100.0% | ↓ | Top 8% |
| Operating margin | -300.6% | -1928.7% | ↑ | Bottom 21% |
| Net margin | -269.7% | -1776.0% | ↑ | — |
| Free-cash-flow margin | -148.3% | -1550.4% | ↑ | — |
| Return on invested capital | -43.7% | — | Bottom 30% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -14.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 37.0%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -43.22%
- Shareholder yield
- -43.22%
- Share count change, 1 year
- +29.5%
- Share count change, 3-year CAGR
- +20.5%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 8
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +36.4%
- Average 2-day reaction, last 8
- +3.3%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $8.00
- Target vs current price
- +118.0%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 63%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | +28.8% | +10.1% | +16.6% | +9.7% | — |
| May 12, 2026 | +51.9% | -3.3% | -9.6% | -17.9% | -2.5% |
| Mar 10, 2026 | +39.4% | +16.5% | +8.7% | +42.4% | +18.4% |
| Nov 12, 2025 | +25.7% | +8.9% | +24.4% | +22.2% | +59.3% |
| Aug 14, 2025 | +8.9% | +4.2% | +15.8% | +33.4% | +48.8% |
| May 6, 2025 | +10.6% | -3.1% | +7.4% | +13.8% | -5.1% |
| Mar 10, 2025 | +20.8% | -9.0% | +1.2% | -8.3% | +27.1% |
| Nov 6, 2024 | +8.5% | +2.3% | -10.9% | -26.4% | -14.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.14 | -$0.20 | +28.8% | $5.7M |
| May 12, 2026 | -$0.13 | -$0.27 | +51.9% | $4.6M |
| Mar 10, 2026 | -$0.20 | -$0.33 | +39.4% | $5.6M |
| Nov 12, 2025 | -$0.26 | -$0.35 | +25.7% | $6.5M |
| Aug 14, 2025 | -$0.41 | -$0.45 | +8.9% | — |
| May 6, 2025 | -$0.42 | -$0.47 | +10.6% | — |
| Mar 10, 2025 | -$0.38 | -$0.48 | +20.8% | $4.0M |
| Nov 6, 2024 | -$0.43 | -$0.47 | +8.5% | $3.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 8.93× | — | — | Bottom 33% |
| Free-cash-flow yield | -15.92% | — | — | Bottom 29% |
| Earnings yield | -21.53% | — | — | Bottom 31% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -0.8%
- 200-day average slope (20 days)
- +7.9%
- Distance from 50-day average
- -26.3%
- Distance from 200-day average
- -5.5%
- RSI (14)
- 29.8
- Relative volume
- 1.47×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 84.6%
- Volatility vs own 5-year history
- 29th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.28
- Correlation with S&P 500
- 0.17
- Current drawdown from 1-year high
- -44.6%
- Maximum drawdown, 3 years
- -90.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 10, 2021 | Apr 8, 2025 | -99.3% | 1044 days | Not yet recovered |
| Oct 7, 2020 | Oct 21, 2020 | -36.2% | 10 days | 11 days (Nov 5, 2020) |
| Dec 24, 2020 | Jan 5, 2021 | -32.8% | 6 days | 24 days (Feb 9, 2021) |
| Nov 19, 2020 | Nov 25, 2020 | -17.5% | 4 days | 10 days (Dec 10, 2020) |
| Nov 5, 2020 | Nov 10, 2020 | -14.1% | 3 days | 3 days (Nov 13, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $208.9M
- EPS, diluted (TTM)
- -$0.79
- Revenue (TTM)
- $22.4M
- 52-week range
- $1.15 – $6.83
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.0M | $12.1M |
| Gross profit | $0 | $0 | $0 | $7.0M | $10.4M |
| Operating income | -$113.7M | -$123.5M | -$132.3M | -$139.7M | -$104.6M |
| Net income | -$111.7M | -$115.4M | -$121.8M | -$127.2M | -$99.5M |
| EPS (diluted) | -$2.33 | -$2.27 | -$2.02 | -$1.68 | -$1.29 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $4.0M | $0 | $0 | $6.5M | $5.6M | $4.6M | $5.7M |
| Net income | -$32.3M | -$28.7M | -$32.1M | -$31.2M | -$19.7M | -$16.5M | -$10.4M | -$13.9M |
| EPS (diluted) | -$0.43 | -$0.38 | -$0.42 | -$0.41 | -$0.26 | -$0.26 | -$0.13 | -$0.14 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$83.5M | -$83.7M | -$107.1M | -$102.9M | -$56.3M |
| Capital expenditure | -$2.3M | -$3.0M | -$3.5M | -$764,000 | -$67,000 |
| Free cash flow | -$85.9M | -$86.7M | -$110.6M | -$103.7M | -$56.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $161.4M | $815,000 | $136.4M | $439,000 | $25.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $151.8M
- Total assets
- $189.4M
- Total liabilities
- $55.6M
- Total debt
- $17.6M
- Net debt
- -$8.7M
- Shareholders’ equity
- $133.7M
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 3,626,569
- Days to cover
- 9.00
- Change vs previous report
- +0.9%
FINRA short interest, settlement date Sep 15, 2026.